Lambova et al., 2019 - Google Patents
Systemic sclerosisLambova et al., 2019
- Document ID
- 1659022534857355856
- Author
- Lambova S
- Müller-Ladner U
- Publication year
- Publication venue
- Genomic and Precision Medicine
External Links
Snippet
Systemic sclerosis (SSc) is a chronic, multisystem connective tissue disease, which is characterized by microangiopathy, fibrosis of the skin and internal organs, and activation of humoral as well as cellular immune responses. The contemporary diagnostic concept …
- 206010042953 Systemic sclerosis 0 title abstract description 366
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7344337B2 (en) | Use of myostatin inhibitors and combination therapy | |
| Guo et al. | Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies | |
| Desbois et al. | Systemic sclerosis: an update in 2016 | |
| Genth et al. | Immunogenetic associations of scleroderma‐related antinuclear antibodies | |
| Fulkerson et al. | Targeting eosinophils in allergy, inflammation and beyond | |
| JP6108660B2 (en) | Kinase inhibitors using cell penetrating peptides | |
| Ammirati et al. | Immunomodulating therapies in acute myocarditis and recurrent/acute pericarditis | |
| TWI744617B (en) | Methods of treating ulcerative colitis | |
| Steen et al. | Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. | |
| Mayes et al. | Systemic sclerosis | |
| Fijolek et al. | Eosinophilic granulomatosis with polyangiitis–advances in pathogenesis, diagnosis, and treatment | |
| KR20170069262A (en) | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide | |
| KR20120105429A (en) | Methods of treating inflammation | |
| KR20170031245A (en) | Methods and compositions for diagnosing and treating inflammatory bowel disorders | |
| Adeeb et al. | Knitting the threads of silk through time: Behcet’s disease—past, present, and future | |
| Lambova et al. | Systemic sclerosis | |
| US20220290246A1 (en) | Single nucleotide polymorphisms and uses thereof | |
| WO2012082771A1 (en) | Cardiac glycosides for treating autoimmune disease | |
| Fam | Recent advances in the management of adult myositis | |
| Hamed et al. | Association of interleukin-6 and its-174G/C promoter polymorphism with clinical and laboratory characteristics of non hepatitis C virus rheumatoid arthritis patients | |
| Assassi et al. | Systemic Sclerosis (Scleroderma) | |
| Wisłowska | Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study | |
| Gerli | Cardiovascular risk in rheumatoid arthritis | |
| WO2007096596A2 (en) | Use of il-8 for the treatment of crohn' s disease | |
| Kameda et al. | Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. |